Vanda Pharma's Trade Secrets Suit Against FDA Moves Forward
By Dean Seal
A federal court has denied the government's bid to throw out a lawsuit from Vanda Pharmaceuticals accusing the Food and Drug Administration of handing trade secrets to generic drug makers.
Vanda said on Friday that the U.S. Court of Federal Claims permitted some of its claims against the government to proceed following oral arguments on a motion to dismiss last week.
The biopharmaceutical company said in its lawsuit filed in May that the FDA improperly provided confidential details about its sleep-wake disorder drug Hertlioz and its schizophrenia treatment Fanapt to generic drug manufacturers while it reviewed Vanda's new drug applications.
Vanda is seeking compensation and will now engage in discovery to support its claims, the company said Friday.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 19, 2024 16:42 ET (21:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise